Abstract
Abstract: A recent study has claimed that nearly 17,000 people in the U.S. and five other countries died prematurely during the early stages of the COVID-19 pandemic due to the compassionate use of hydroxychloroquine (HCQ) for treatment. However, this study's conclusions are contentious due to reliance on flawed data and the neglect of significant evidence supporting HCQ's efficacy in early outpatient treatment. Our critique challenges the validity of the study, highlighting its methodological weaknesses and the confounding factors it overlooked. By reviewing the comprehensive body of scientific literature, we demonstrate that treatment with HCQ, particularly in combination with zinc and antibiotics, consistently yielded positive outcomes, especially in the early stages. This work aims to provide a balanced and objective assessment of HCQ's impact on COVID-19, emphasizing the importance of early intervention and proper dosage.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
